The Israel Institute for Biological Research has completed the
development phase of Covid-19 antibody.
As researchers and
medical labs are stepping up their efforts to find a cure for Covid-19, the Isreal
Defence Ministry said in a statement that the Israel Institute for
Biological Research (IIBR) has completed the development phase of coronavirus
antibody or passive vaccine, reports The Jerusalem Post.
The Israeli defence
minister was briefed by the research team, who told that this antibody attacks
the virus and neutralises it in the body. The institute is now preparing to get
a patent for the antibody and contract for its commercial development. The
defence ministry of Israel will coordinate this with the IIBR.
“I am proud of the
Biological Institute staff, who have made a major breakthrough,” Defence
Minister Naftali Bennett said Monday. “The Jewish creativity and ingenuity
brought about this amazing achievement.”
Last month, IIBR
told that it had begun testing the antibody-based vaccine prototype on rodents.
The institute is also involved in plasma collection from people who have
recovered from the novel coronavirus infection, hoping that this might help
research.
A second Israeli
research team, MigVax, has also reported that it is close to completing the
first phase of development of a coronavirus
vaccine. Last week, it secured a $12 million investment from OurCrowd to
accelerate the path to clinical trials.
Israel has tested
over 404,000 samples in the country and 16,246 came out positive. The country
has reported 235 deaths till now.
No comments:
Post a Comment